Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

A. Pietrangelo, MD, PhD, P. Brissot, MD, H. Bonkovsky, MD, C. Niederau, L. Rojkjaer, R. Weitzman, J. Bodner, S. Bailey, Pradyumna D. Phatak, MD

Blood (2007) 110 (11): 2680.

https://doi.org/10.1182/blood.V110.11.2680.2680

Published: 2007

Journal Articles

Correlation between Dose-Dependent Reductions in Serum Transaminase (ALT) and Serum Ferritin Levels during Long-Term Chelation Therapy with Deferasirox (Exjade®, ICL670).

P. Brissot, Y. Deugnier, P. Cianciulli, H. Cario, M. Jeng, B. Rabault

Blood (2006) 108 (11): 3817.

https://doi.org/10.1182/blood.V108.11.3817.3817

Published: 2006

Journal Articles

Non Invasive Assessment of Hepatic Fibrosis by Measurement of Liver Stiffness in Post Transfusional Iron Overload: Preliminary Results in 15 Patients.

T. Mirault, MD, D. Lucidarme, MD, B. Turlin, MD PhD, Y. Deugnier, MD PhD, P. Brissot, MD PhD, K. Kanaan, MD, J.L. Demory, MD, P. Gosset, MD, P. Vandevenne, MD, A. Charpentier, MD, O. Ernst, MD, PhD, Christian Rose, MD

Blood (2006) 108 (11): 3740.

https://doi.org/10.1182/blood.V108.11.3740.3740

Published: 2006

Journal Articles

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

P. Brissot, B. Turlin, G.L. Forni, G. Alimena, G. Quarta, D. Selleslag, A. Thompson, F. Locatelli, A. Berretta, M. de Montalembert, C. Ressayre-Djaffer, B. Rabault, J. Ford, D. Alberti

Blood (2005) 106 (11): 823.

https://doi.org/10.1182/blood.V106.11.823.823

Published: 2005

Journal Articles

A Point Mutation in the Bulge of the Iron-Responsive Element of the L Ferritin Gene in Two Families With the Hereditary Hyperferritinemia-Cataract Syndrome

M.E. Martin, S. Fargion, P. Brissot, B. Pellat, C. Beaumont

Blood (1998) 91 (1): 319–323.

https://doi.org/10.1182/blood.V91.1.319

Published: 1998

NARROW

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

Correlation between Dose-Dependent Reductions in Serum Transaminase (ALT) and Serum Ferritin Levels during Long-Term Chelation Therapy with Deferasirox (Exjade®, ICL670).

Non Invasive Assessment of Hepatic Fibrosis by Measurement of Liver Stiffness in Post Transfusional Iron Overload: Preliminary Results in 15 Patients.

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

A Point Mutation in the Bulge of the Iron-Responsive Element of the L Ferritin Gene in Two Families With the Hereditary Hyperferritinemia-Cataract Syndrome

Email alerts

ASH Publications

American Society of Hematology

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

Correlation between Dose-Dependent Reductions in Serum Transaminase (ALT) and Serum Ferritin Levels during Long-Term Chelation Therapy with Deferasirox (Exjade®, ICL670).

Non Invasive Assessment of Hepatic Fibrosis by Measurement of Liver Stiffness in Post Transfusional Iron Overload: Preliminary Results in 15 Patients.

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

A Point Mutation in the Bulge of the Iron-Responsive Element of the L Ferritin Gene in Two Families With the Hereditary Hyperferritinemia-Cataract Syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only